Sustainability Management Report Released
ESG Social (S) Rating Upgraded to A+
"Minimizing Career Interruptions Through Return-to-Work Support and Flexible Work"
"Organizational Culture Achievements Including Selection as a Leading Family-Friendl

Daewoong Pharmaceutical has achieved a high parental leave return rate and revealed its organizational culture achievements aimed at reducing career interruptions after returning to work.


Daewoong Pharmaceutical employees are having a meeting at the 'Daewoong Pharmaceutical Communication Lounge.' Daewoong Pharmaceutical

Daewoong Pharmaceutical employees are having a meeting at the 'Daewoong Pharmaceutical Communication Lounge.' Daewoong Pharmaceutical

View original image

The company announced on July 14 that the return-to-work rate for employees who took parental leave in 2024 reached 96%.


As the government expands the parental leave system, Daewoong Pharmaceutical explained that it operates a support system enabling employees to smoothly return to work after their leave. The government plans to improve the system starting August 20, allowing employees with children under the age of eight to take parental leave in 1- or 2-week increments.


Daewoong Pharmaceutical has maintained the Ministry of Gender Equality and Family’s “family-friendly company” certification for 12 consecutive years, and was also selected as a “leading family-friendly company,” a newly established recognition this year. Since first receiving certification as a family-friendly company in 2008, the company has renewed its certification every three years, and in 2022 was named a “top family-friendly company.”


According to the company, a communication system is in place in which the returning employee, their previous department, and the HR team discuss the return-to-work plan together before the employee’s reinstatement. The internal “Career Development Program (CDP)” is also offered to support employees with career transitions.


Alongside the flexible work system, Daewoong Pharmaceutical runs several programs, including the “Daewoong Guardian 1:1 Exercise Program” for female employees who return to work within one year of giving birth, and the “No-Questions-Asked Vacation Campaign,” which allows employees to take leave without providing a reason.


A representative from Daewoong Pharmaceutical stated, “There is a strong perception within our organization that parenting should not be a disadvantage to one’s career, and we strive to create a workplace environment where employees can balance work and parenting while working autonomously.”


Daewoong Pharmaceutical earned an A+ grade in the social (S) category of the Korea ESG Standards Institute’s 2025 ESG evaluation. Its overall rating improved from B to A, and its environmental (E) category rating also rose from B+ to A.



In addition, the company obtained the Ministry of Health and Welfare and Korea Health Promotion Institute’s “health-friendly company” certification, as well as the Ministry of Gender Equality and Family’s “leading family-friendly company” certification. Since 2023, Daewoong Pharmaceutical has published a sustainability report, and this year’s report presents “CARE for People and Planet” as the core direction for sustainable management.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing